The potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy.

Thomas Klein, Vasken Dilsizian, Q. Cao, Wengen Chen, Timm Michael Dickfeld

Research output: Contribution to journalArticle

Abstract

Implantable cardioverter-defibrillators (ICDs) significantly reduce mortality in patients with depressed left ventricular ejection fraction (LVEF) and heart failure (HF). However, shortcomings of LVEF to accurately identify those at greatest risk of ventricular tachyarrhythmias have led to the pursuit of alternative means to refine qualification criteria for ICD implantation. It is well established that imaging the cardiac nervous system with(123)I meta-iodobenzylguanidine ((123)I-mIBG) provides incremental prognostic value in patients with HF beyond LVEF. Whether (123)I-mIBG will also play an important role for identifying and/or predicting sustained ventricular tachyarrhythmias in patients with cardiomyopathy and determining those who may benefit from ICD implantation is currently under investigation. Novel imaging approaches that pinpoint the site of ventricular arrhythmias and guide ventricular tachycardia ablation are presented.

Original languageEnglish (US)
Pages (from-to)359
Number of pages1
JournalCurrent Cardiology Reports
Volume15
Issue number5
DOIs
StatePublished - May 2013
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy.'. Together they form a unique fingerprint.

  • Cite this